Biostax

Biostax FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Biostax (BTAX) as of Nov 1, 2026 is 17.27 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 30.59 % — a change of -43.55% (lower).

FCF Conversion

17.27 %

YoY

-43.55%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Biostax is 2023 17.27 % . FCF Conversion Rate (FCF/EBITDA) of Biostax was 2022 30.59 % . It decreases by -43.55% lower compared to the previous year.

The Biostax FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2016
14.56 USD
Jan 1, 2017
28.09 USD
Jan 1, 2018
16.78 USD
Jan 1, 2019
0.03 USD
Jan 1, 2020
-12.08 USD
Jan 1, 2021
-6.46 USD
Jan 1, 2022
30.59 USD
Jan 1, 2023
17.27 USD
The Biostax FCF Conversion history
YEARFCF ConversionYoY
17.27 %-43.55%
30.59 %-573.47%
-6.46 %-46.52%
-12.08 %-44,042.54%
0.03 %-99.84%
16.78 %-40.27%
28.09 %+92.96%
14.56 %-26.81%
19.89 %+145.94%
8.09 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biostax Stock analysis

What does Biostax do? Immune Therapeutics, Inc. develops and markets pharmaceutical, biotechnology, and MedTech products through its subsidiary BiostaxRx, which focuses on treating inflammaging disease. The company's product portfolio includes Londonal, a once-a-day immune system regulator for HIV/AIDS management, and JKB-122, a therapy targeting Autoimmune Hepatitis, NAFLD, and NASH with anti-fibrotic and anti-inflammatory properties. Biostax has partnerships in autoimmunity and immune restoration fields to deliver solutions for patients with autoimmunity, chronic inflammation, infection, and cancer. BiostaxRx specifically addresses inflammaging disease within its treatment focus. Biostax Corp's revenue streams come from the sale of Londonal and JKB-122 to healthcare providers and patients seeking treatments for immune-related conditions. The company markets its products to medical professionals and institutions specializing in autoimmune disorders, chronic inflammation, and oncology. Its focus on specific therapeutic areas allows it to target healthcare segments requiring immune modulation and anti-inflammatory solutions. The company's partnerships support its delivery of specialized treatments for chronic conditions such as HIV/AIDS, liver diseases, and cancer-related inflammation. The company's product lines are designed for specific patient segments including those with HIV/AIDS, Autoimmune Hepatitis, NAFLD, NASH, and inflammaging. Londonal is positioned for HIV/AIDS management while JKB-122 targets liver conditions and inflammation. BiostaxRx's focus on inflammaging disease aligns with the growing market for age-related immune health solutions. The company's marketing strategy emphasizes specialized treatments for complex conditions where current therapies are limited or ineffective. Biostax is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biostax stock

FCF Conversion Rate (FCF/EBITDA) of Biostax is 17.27 % in 2023.

FCF Conversion Rate (FCF/EBITDA) of Biostax changed from 30.59 % to 17.27 %, representing a -43.55% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Biostax since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Biostax with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Biostax

All Key Metrics — Biostax